Sunday, August 10, 2014
Review of interleukin-2 as intra-lesional melanoma treatment
Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review. Byers, et al. J Surg Oncol. 2014. July.
Authors searched databases to find studies evaluating the clinical response to IL-2 for in-transit melanoma done from 1980-2012. Data was then pooled and analyzed to determine lesion and patient responses. 49 studies found. 43 didn't meet criteria. Of 6 observational trials - dose, treatment interval, and response rate were variable. Overall, 2,182 lesions and 140 patients were treated in these studies. Pooling the lesions, complete response was seen in 78%. Pooling subjects, 50% achieved a complete response. Treatment was generally well tolerated. Side effects were: localized pain and swelling, mild flu-like symptoms. Only 3 grade 3 adverse events were noted: including rigors, headache, and fever with arthralgia. Conclusion: Intra-lesional IL-2 safely and effectively provides locoregional control of in-transit melanoma.
While the specifics and exact "how to's" are a little vague here, the response sounds pretty good. Y'all know I'm a fan of looking deeper into intralesional therapy!!!! Best - c